In addition, bromodomain-containing 4 (BRD4) inhibition was shown to prevent cell proliferation and epithelial–mesenchymal transition (EMT) and play an anti-tumour role in RCC by activating the NF-κB–NLRP3–caspase-1 pyroptosis signalling pathway [84]. Here, NLRP3 is linked to neoplasm.